Insider Selling: Phreesia, Inc. (NYSE:PHR) CFO Sells 886 Shares of Stock

Phreesia, Inc. (NYSE:PHR - Get Free Report) CFO Balaji Gandhi sold 886 shares of the company's stock in a transaction dated Thursday, July 17th. The shares were sold at an average price of $26.89, for a total value of $23,824.54. Following the completion of the sale, the chief financial officer directly owned 106,661 shares of the company's stock, valued at approximately $2,868,114.29. This trade represents a 0.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Phreesia Stock Down 2.2%

Phreesia stock traded down $0.61 during midday trading on Thursday, reaching $27.09. The stock had a trading volume of 420,413 shares, compared to its average volume of 577,443. The stock has a market capitalization of $1.61 billion, a P/E ratio of -36.60 and a beta of 0.72. The firm's fifty day simple moving average is $26.58 and its 200-day simple moving average is $26.43. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.95 and a current ratio of 1.95. Phreesia, Inc. has a 1-year low of $17.07 and a 1-year high of $30.53.

Phreesia (NYSE:PHR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 28th. The company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.13) by $0.06. Phreesia had a negative return on equity of 16.23% and a negative net margin of 9.83%. The company had revenue of $115.94 million during the quarter, compared to analysts' expectations of $115.00 million. During the same quarter last year, the company earned ($0.05) EPS. Phreesia's revenue for the quarter was up 14.5% compared to the same quarter last year. As a group, analysts expect that Phreesia, Inc. will post -1.1 EPS for the current fiscal year.

Institutional Trading of Phreesia

Several institutional investors and hedge funds have recently added to or reduced their stakes in PHR. Invesco Ltd. increased its stake in shares of Phreesia by 0.9% during the 4th quarter. Invesco Ltd. now owns 40,249 shares of the company's stock worth $1,013,000 after purchasing an additional 357 shares during the last quarter. Diversified Trust Co increased its position in Phreesia by 1.0% during the second quarter. Diversified Trust Co now owns 45,042 shares of the company's stock worth $1,282,000 after buying an additional 426 shares during the last quarter. NewEdge Advisors LLC increased its position in Phreesia by 12.1% during the fourth quarter. NewEdge Advisors LLC now owns 4,256 shares of the company's stock worth $107,000 after buying an additional 459 shares during the last quarter. Arcadia Investment Management Corp MI raised its stake in Phreesia by 0.7% in the first quarter. Arcadia Investment Management Corp MI now owns 92,770 shares of the company's stock valued at $2,371,000 after buying an additional 615 shares during the period. Finally, QRG Capital Management Inc. lifted its position in shares of Phreesia by 8.0% in the first quarter. QRG Capital Management Inc. now owns 11,118 shares of the company's stock valued at $284,000 after buying an additional 827 shares during the last quarter. 92.10% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Citigroup reissued a "buy" rating on shares of Phreesia in a research report on Wednesday, May 28th. Truist Financial lifted their target price on Phreesia from $34.00 to $35.00 and gave the stock a "buy" rating in a report on Thursday, May 29th. Wall Street Zen raised Phreesia from a "hold" rating to a "buy" rating in a research note on Sunday, June 1st. KeyCorp raised their price target on Phreesia from $28.00 to $35.00 and gave the stock an "overweight" rating in a research report on Monday, July 14th. Finally, Canaccord Genuity Group cut their price objective on Phreesia from $35.00 to $34.00 and set a "buy" rating on the stock in a report on Thursday, May 29th. Eleven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Phreesia presently has an average rating of "Buy" and an average price target of $32.27.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.